

Lihua E Budde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7881900/publications.pdf>

Version: 2024-02-01

42
papers

2,684
citations

430874

18
h-index

315739

38
g-index

42
all docs

42
docs citations

42
times ranked

3713
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
2	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	4.9	124
3	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2697-2708.	1.4	15
4	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	10.7	119
5	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021, 9, 75-88.	3.4	24
6	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	1.8	12
7	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021, 17, 3549-3560.	2.4	10
8	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. <i>Blood Advances</i> , 2021, 5, 4059-4063.	5.2	62
9	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood Advances</i> , 2021, , .	5.2	5
10	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 133-133.	1.4	13
11	Physical Therapy Assessment of Baseline Function and Endurance Predicts Short Term Outcomes in Commercial CAR T Patients with Lymphoma. <i>Blood</i> , 2021, 138, 570-570.	1.4	1
12	ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 2548-2555.	5.2	19
13	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020, 136, 37-38.	1.4	2
14	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	4.9	284
15	Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1386-1393.	2.0	5
16	Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleuce (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. <i>Blood</i> , 2020, 136, 2-3.	1.4	3
17	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. <i>Blood</i> , 2020, 136, 40-41.	1.4	2
18	Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program. <i>Blood</i> , 2020, 136, 10-10.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience. <i>Blood</i> , 2020, 136, 21-22.	1.4	2
20	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. <i>Blood</i> , 2019, 134, 4075-4075.	1.4	10
21	Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1285-1285.	1.4	9
22	Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. <i>Blood</i> , 2019, 134, 760-760.	1.4	23
23	Multi-Institution Phase I/II Continual Re-Assessment Study to Identify the Optimal Dose of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 1535-1535.	1.4	7
24	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	4.9	393
25	CD19 CAR-T therapy and sepsis: dancing with the devil. <i>Blood</i> , 2018, 131, 7-8.	1.4	17
26	Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. <i>Journal of Immunotherapy</i> , 2018, 41, 19-31.	2.4	23
27	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
28	Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. <i>Blood Research</i> , 2018, 53, 223.	1.3	0
29	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018, 183, 601-607.	2.5	7
30	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	8.2	498
31	Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. <i>Journal of Immunotherapy</i> , 2017, 40, 26.		72
32	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869.	2.0	19
33	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	1.6	152
34	Phase 1 studies of central memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , 2016, 127, 2980-2990.	1.4	264
35	Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. <i>Cancer Immunology Research</i> , 2016, 4, 509-519.	3.4	27
36	Comparison of naïve and central memory derived CD8 ⁺ effector cell engraftment fitness and function following adoptive transfer. <i>Oncotarget</i> , 2016, 7, e1072671.	4.6	25

#	ARTICLE	IF	CITATIONS
37	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2016, 128, 104-104.	1.4	14
38	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 830-830.	1.4	3
39	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. Blood, 2016, 128, 2161-2161.	1.4	0
40	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research, 2015, 21, 2993-3002.	7.0	52
41	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 3991-3991.	1.4	9
42	Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma. PLoS ONE, 2013, 8, e82742.	2.5	167